Kovitz Investment Group Partners LLC decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,429 shares of the medical equipment provider’s stock after selling 461 shares during the quarter. Kovitz Investment Group Partners LLC’s holdings in Hologic were worth $753,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Rational Advisors LLC lifted its position in Hologic by 45.8% in the 4th quarter. Rational Advisors LLC now owns 681 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 214 shares in the last quarter. CFM Wealth Partners LLC purchased a new position in shares of Hologic in the fourth quarter worth $39,000. Ancora Advisors LLC purchased a new position in shares of Hologic in the fourth quarter worth $39,000. Pacitti Group Inc. purchased a new position in shares of Hologic in the fourth quarter worth $52,000. Finally, CENTRAL TRUST Co lifted its holdings in shares of Hologic by 44.1% during the fourth quarter. CENTRAL TRUST Co now owns 1,013 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 310 shares in the last quarter. Hedge funds and other institutional investors own 95.15% of the company’s stock.

Shares of NASDAQ:HOLX opened at $32.26 on Thursday. The stock has a market capitalization of $8.28 billion, a price-to-earnings ratio of 35.07, a PEG ratio of 1.55 and a beta of 0.90. The company has a debt-to-equity ratio of 1.23, a quick ratio of 1.20 and a current ratio of 1.57. The stock’s 50-day simple moving average is $45.71 and its two-hundred day simple moving average is $49.47. Hologic, Inc. has a 52-week low of $26.49 and a 52-week high of $55.25.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, January 29th. The medical equipment provider reported $0.61 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.61. Hologic had a net margin of 7.30% and a return on equity of 30.47%. The firm had revenue of $850.50 million during the quarter, compared to analyst estimates of $849.40 million. During the same quarter in the prior year, the firm earned $0.58 EPS. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. As a group, equities analysts forecast that Hologic, Inc. will post 2.64 earnings per share for the current fiscal year.

HOLX has been the subject of several research analyst reports. Piper Sandler lifted their price objective on Hologic from to in a report on Thursday, January 30th. TheStreet upgraded shares of Hologic from a “c” rating to a “b+” rating in a research note on Wednesday, January 29th. BTIG Research restated a “buy” rating and set a $54.00 target price on shares of Hologic in a research note on Thursday, January 30th. Stifel Nicolaus raised their price target on shares of Hologic from $48.00 to $52.00 and gave the company a “hold” rating in a report on Friday, December 13th. Finally, Morgan Stanley lowered shares of Hologic from an “equal weight” rating to an “underweight” rating in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $55.53.

In related news, General Counsel John M. Griffin sold 19,624 shares of Hologic stock in a transaction on Monday, January 13th. The stock was sold at an average price of $52.86, for a total transaction of $1,037,324.64. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 16,348 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $51.73, for a total value of $845,682.04. The disclosure for this sale can be found here. Insiders own 1.00% of the company’s stock.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Market Perform

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.